IPP Bureau
BMS’ Cobenfy sees steady start, eyes stronger growth ahead
By IPP Bureau - October 31, 2025
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Merck’s Capvaxive shows strong momentum amid industry vaccine decline
By IPP Bureau - October 31, 2025
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success
By IPP Bureau - October 31, 2025
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
FDA issues warning letter to Philips over manufacturing and quality system deficiencies
By IPP Bureau - October 31, 2025
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials
By IPP Bureau - October 31, 2025
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
GSK signs $745 million licensing agreement with Empirico for novel respiratory siRNA therapy
By IPP Bureau - October 31, 2025
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
India’s healthcare and pharma sectors recorded a total of 72 transactions valued at US$ 3.5 billion in Q3 2025: Grant Thornton Bharat
By IPP Bureau - October 31, 2025
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
FUJIFILM India unveils FW500, advancing biochemistry innovation in diagnostics
By IPP Bureau - October 31, 2025
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
EU approves Alexion’s Koselugo to treat adults with neurofibromatosis type 1 tumours
By IPP Bureau - October 31, 2025
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Shaquille O’Neal and Lilly join forces to tackle sleep apnea awareness
By IPP Bureau - October 31, 2025
Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their
Alexion highlights breakthrough C5 inhibition advances in gMG at 2025 AANEM and MGFA scientific sessions
By IPP Bureau - October 31, 2025
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
RestorixHealth acquires CutisCare to expands wound care portfolio
By IPP Bureau - October 31, 2025
